Another phase I/II clinical study is being conducted to assess the safety and efficacy of treatment with anti-MUC1 CAR-T cells combined with programmed cell death protein 1 (PD-1) knockout for patients with advanced NSCLC (NCT03525782). The gene discussed is MUC1; the disease is non-small cell lung carcinoma.